Healthcare Fraud: Novo Nordisk Inc. Agrees to Pay to Resolve Allegations That The Company Failed to Comply For Its Type II Diabetes Medication
Novo Nordisk Agrees to Pay $58 Million For Failure to Comply With FDA-Mandated Risk Program Payments Resolve Allegations Highlighted…